Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice
about
A commensal Helicobacter sp. of the rodent intestinal flora activates TLR2 and NOD1 responses in epithelial cellsRole of regulatory T cell in the pathogenesis of inflammatory bowel diseaseRelationship between intestinal microbiota and colorectal cancerColitis and colon cancer in WASP-deficient mice require helicobacter species.Differential susceptibility of P-glycoprotein deficient mice to colitis induction by environmental insults.Toll-like receptors in inflammatory bowel diseases: a decade later.Prevalence and spread of enterohepatic Helicobacter species in mice reared in a specific-pathogen-free animal facilityThe interaction of gut microbes with host ABC transporters.Detection, eradication, and research implications of Helicobacter infections in laboratory rodents.Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammationUlcerative typhlocolitis associated with Helicobacter mastomyrinus in telomerase-deficient miceMacroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene.Lack of effect of murine norovirus infection on a mouse model of bacteria-induced colon cancer.Dual infection with Helicobacter bilis and Helicobacter hepaticus in p-glycoprotein-deficient mdr1a-/- mice results in colitis that progresses to dysplasia.The role of estrogen signaling in a mouse model of inflammatory bowel disease: a Helicobacter hepaticus model.Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs.Murine models of ulcerative colitis.Enterohepatic Helicobacter species are prevalent in mice from commercial and academic institutions in Asia, Europe, and North America.Inoculation with enterococci does not affect colon inflammation in the multi-drug resistance 1a-deficient mouse model of IBD.The struggle within: microbial influences on colorectal cancer.Prevalence of murine Helicobacter spp. Infection is reduced by restocking research colonies with Helicobacter-free mice.Animal models of intestinal inflammation: ineffective communication between coalition members.Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota.Layers of mutualism with commensal bacteria protect us from intestinal inflammation.Environment as a critical factor for the pathogenesis and outcome of gastrointestinal disease: experimental and human inflammatory bowel disease and helicobacter-induced gastritis.Role of chitotriosidase (chitinase 1) under normal and disease conditions.Keratinocyte growth factor-2 stimulates P-glycoprotein expression and function in intestinal epithelial cells.Microbial and histopathologic considerations in the use of mouse models of inflammatory bowel diseases.Bacterial infection of Smad3/Rag2 double-null mice with transforming growth factor-beta dysregulation as a model for studying inflammation-associated colon cancer.Cytolethal distending toxin promotes Helicobacter cinaedi-associated typhlocolitis in interleukin-10-deficient mice.Effects of Helicobacter infection on research: the case for eradication of Helicobacter from rodent research coloniesMurine norovirus: an intercurrent variable in a mouse model of bacteria-induced inflammatory bowel disease.Chronic hepatitis, hepatic dysplasia, fibrosis, and biliary hyperplasia in hamsters naturally infected with a novel Helicobacter classified in the H. bilis cluster.P-glycoprotein induction by breast milk attenuates intestinal inflammation in experimental necrotizing enterocolitis.Helicobacter hepaticus infection in mice: models for understanding lower bowel inflammation and cancer.Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice.The other Helicobacters.Of mice and microflora: considerations for genetically engineered mice.Overview of mouse models of inflammatory bowel disease and their use in drug discovery.Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: preclinical and clinical observations.
P2860
Q21143791-1986B969-31B4-4386-9C79-EB455E08C835Q26768560-F09DC19C-3611-4E03-A84E-986877D809A2Q26781449-85B4B705-843C-4A08-9055-785F91C0633BQ33849131-8F93BC25-C9B4-40D2-BB05-260DD3F6FB5FQ33921440-00759CCE-BFBB-4F57-9825-A49689838477Q34134813-E7A7A5DE-EB53-4A6B-9581-B1A0CAC6ACD5Q34431750-6FAC1572-7D5A-43AE-BB60-463B9A5CE6B9Q34503647-53F8E8F4-E8D3-428B-8E07-94C977D4D59DQ34542832-33462AE1-B77E-4B31-A811-287D50AC05D0Q34768240-804D93E6-95FC-4EE8-9536-AA877399FC30Q34836569-7B4C110F-4C10-4EA8-B768-55DAFAE2E2ECQ35047787-303D487B-6BEE-4C88-A0B9-C0DC7D247381Q35069825-52D70891-D4EA-478D-9893-130A36BB71FFQ35083876-E98A7E6A-3FD9-4AAD-BB7A-8F3E8130D633Q35141666-61E6F530-5E82-4C35-B1D8-7EFB9A6510D5Q35164664-DA170D4F-0211-428D-90CE-2E65DF6061E4Q35183693-4DE365BC-E717-46C5-91A3-83AE8A2484CAQ35913788-835D483D-DE7D-46DA-89D6-3CBE85D8ADD4Q35945444-9B17D8AD-DD0E-439D-92DD-64BE056D6C69Q36036277-209DB6EE-E358-4E14-8264-E862E3075F55Q36105091-F8D4A453-76B5-42AA-99CB-0CB0E87F40FBQ36199730-99404D7B-D2FE-4BB7-B04F-5A3B23EFB914Q36209737-47CC9401-967E-4E06-A072-54FD871A9FA3Q36366156-9A23D902-5F1F-409D-9EFD-9EB369AAD334Q36438490-E895AA29-F609-4A4B-8393-5A2AF4228164Q36630259-3CD8E067-FAA1-4F6F-88EC-4D59881EBA4DQ36699729-8BEC7D0A-0082-468C-BD92-E8772DDD7BB3Q37070484-13F68072-A215-4E30-BA6E-97CCEDD6A68AQ37073835-C8F6D976-D98F-41A0-BFC3-E08DE9EFBE15Q37204542-AF5D8249-7798-4DC3-8FC5-CF846F693F5EQ37243805-6F67B3F7-5AA0-4F83-802C-C86DB7DB1FC8Q37261984-46592177-015F-4C9F-AA22-C779977E2AB6Q37410483-F4122AFE-6585-4094-A644-8B7BECB5C623Q37540633-5719B195-008D-405A-BAAA-DC4D28DFBAA6Q37612291-0D04BB15-DBBF-4257-B736-1E09295C6370Q37723134-D53D6070-F735-4ECB-B6BD-0FAFF8BFC078Q37928114-22495606-0D75-4909-86AA-CF12933824E8Q37968970-54E0659E-A0A0-424F-BA52-20D26A2F3253Q37980400-40D45A70-E058-4FC9-A806-CFD9413E612FQ38029557-6E460174-C4BE-4FC1-8F4B-4EB65BF66AA9
P2860
Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Helicobacter bilis infection a ...... ance-deficient (mdr1a-/-) mice
@ast
Helicobacter bilis infection a ...... ance-deficient (mdr1a-/-) mice
@en
type
label
Helicobacter bilis infection a ...... ance-deficient (mdr1a-/-) mice
@ast
Helicobacter bilis infection a ...... ance-deficient (mdr1a-/-) mice
@en
prefLabel
Helicobacter bilis infection a ...... ance-deficient (mdr1a-/-) mice
@ast
Helicobacter bilis infection a ...... ance-deficient (mdr1a-/-) mice
@en
P2093
P2860
P1476
Helicobacter bilis infection a ...... ance-deficient (mdr1a-/-) mice
@en
P2093
Andrew Burich
Donna Shows
Joanne L Viney
Kim Waggie
Lillian Maggio-Price
Phil Morrissey
Sabine Escobar
Weiping Zeng
P2860
P304
P356
10.1016/S0002-9440(10)64894-8
P407
P577
2002-02-01T00:00:00Z